Russell Beyer - 17 Nov 2021 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Financial Officer
Signature
/s/ Russell P. Beyer
Issuer symbol
SABS
Transactions as of
17 Nov 2021
Net transactions value
$0
Form type
4
Filing time
19 Nov 2021, 15:45:07 UTC
Previous filing
22 Oct 2021
Next filing
18 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +110,000 $0.000000 110,000 17 Nov 2021 Common Stock 110,000 $11.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.